Any current/future new fundraising through debt or equity?

The transcript from the Q2 FY24 earnings call does not mention any current or planned fundraising through debt or equity. No discussions or questions on new debt or equity issuance were raised during the call. The company is focusing on aggressive CAPEX and expansion plans funded through internal accruals or existing resources. There are no indications of immediate plans for external fundraising within the provided transcript. Shareholding compliance deadline mentioned is by May 2025, but no related fundraising mentioned.

Any current/future capex/capital investment/strategic investment?

CAPEX plans advancing aggressively on Greenfield manufacturing Sites 3++, Site-IV, and Site-V. Site-III+ and 3++: Machinery and equipment procurement underway; regulatory approvals applied. Planned production of 3-5 products in agrochemicals and pharmaceuticals upon commercialization of Site-III+ and 3++. Site-IV: Construction ongoing; expected operational by end of current financial year; initially dedicated to contract/exclusive manufacturing, especially oilfield services agreement with US company. Secondary construction at Site-IV planned for commercialization agreement with Saudi Aramco Te

Future growth expectations in sales/revenue/volumes?

Management expects growth driven primarily by volume increases, despite a 25% year-on-year reduction in realizations due to pricing pressure and Chinese dumping across both pharma and agro segments. Export contribution is expected to rise, aiming to return to a balanced 50:50 domestic-export revenue mix from the current 66% domestic sales. New product launches, especially in agrochemicals, are on track with no anticipated delays, and these are expected to contribute to topline growth progressively. Anticipated full-fledged implementation of the oil field services segment in the next fiscal yea

Future growth expectations in earnings/operating earnings/profits/EPS?

Management targets gross margins to improve from current 50-53% range to around 55-56% over the next 2-3 years, indicating margin expansion. EBITDA grew 18% YoY in H1 FY24 and PAT grew 18%, showing solid profitability growth. Expect full-fledged implementation and revenue ramp-up from the new oilfield services segment starting FY25. New product launches in agrochemical and pharmaceutical segments anticipated to contribute significantly in next 3-4 quarters. Export contribution expected to increase from current 34% to around 50%, broadening revenue base. Reduction in raw material prices and sta

Current/ Expected Orderbook/ Pending Orders?

The company has good visibility on order books for contractual exclusive manufacturing with multiyear contracts and minimum quantity commitments, renegotiated yearly based on raw material prices. Large-scale manufacturing has good previous year visibility but currently cautious on new large orders due to volatile pricing and raw material instability. Upcoming orders include approx. Rs. 300 crores (~1600 metric tons) from initial products in MENA region with no impact from current geopolitical tensions. Agrochemical segment shows revival in orders with demand and deliveries expected in Q3 and Q

IN US

Sale is live|00:00:00left today

Aether Industries LtdQ3 FY23Chemicals & Petrochemicals

Aether Industries Ltd Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,325P/E: 65.2Market Cap: ₹14.7K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

Yes

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Management expects growth driven primarily by volume increases, despite a 25% year-on-year reduction in realizations due to pricing pressure and Chinese dumping across both pharma and agro segments.
→Export contribution is expected to rise, aiming to return to a balanced 50:50 domestic-export revenue mix from the current 66% domestic sales.
→New product launches, especially in agrochemicals, are on track with no anticipated delays, and these are expected to contribute to topline growth progressively.
→Anticipated full-fledged implementation of the oil field services segment in the next fiscal year, with additional products expected from existing clients and potential new customers.
→Recovery signs in agrochemical sector orders, with inventory destocking tapering off and new orders expected in the next two quarters.
→Ramp-up from strategic partnerships (e.g., Otsuka) is expected to gradually increase volumes.
→Overall, management is confident of improving margins alongside volume growth to sustain future revenue growth.

Margin guidance

Category 1

→Management targets gross margins to improve from current 50-53% range to around 55-56% over the next 2-3 years, indicating margin expansion.
→EBITDA grew 18% YoY in H1 FY24 and PAT grew 18%, showing solid profitability growth.
→Expect full-fledged implementation and revenue ramp-up from the new oilfield services segment starting FY25.
→New product launches in agrochemical and pharmaceutical segments anticipated to contribute significantly in next 3-4 quarters.
→Export contribution expected to increase from current 34% to around 50%, broadening revenue base.
→Reduction in raw material prices and stable average selling prices support margin expansion.
→Volume-driven growth expected to sustain despite price pressures, with product mix improvements.
→Inventory and receivables management improving, supporting operational efficiency and profitability.
→Overall, management is optimistic on earnings growth driven by volume increase, margin expansion, new product additions, and diversification into new geographies and sectors.

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript from the Q2 FY24 earnings call does not mention any current or planned fundraising through debt or equity.
→No discussions or questions on new debt or equity issuance were raised during the call.
→The company is focusing on aggressive CAPEX and expansion plans funded through internal accruals or existing resources.
→There are no indications of immediate plans for external fundraising within the provided transcript.
→Shareholding compliance deadline mentioned is by May 2025, but no related fundraising mentioned.

Order book

Yes

→The company has good visibility on order books for contractual exclusive manufacturing with multiyear contracts and minimum quantity commitments, renegotiated yearly based on raw material prices.
→Large-scale manufacturing has good previous year visibility but currently cautious on new large orders due to volatile pricing and raw material instability.
→Upcoming orders include approx. Rs. 300 crores (~1600 metric tons) from initial products in MENA region with no impact from current geopolitical tensions.
→Agrochemical segment shows revival in orders with demand and deliveries expected in Q3 and Q4 of FY24 after Q2 production buildup.
→New contracts in oilfield services are in commissioning and trial order phase with expected full-fledged implementation next fiscal year, including additional products under discussions.
→New product launches in pharma and agrochemicals have started contributing to topline; gradual volume increases expected.
→No expected delays in new or existing product launches; some partnerships and programs to be announced shortly.

Capex plans

Yes

→CAPEX plans advancing aggressively on Greenfield manufacturing Sites 3++, Site-IV, and Site-V.
→Site-III+ and 3++: Machinery and equipment procurement underway; regulatory approvals applied.
→Planned production of 3-5 products in agrochemicals and pharmaceuticals upon commercialization of Site-III+ and 3++.
→Site-IV: Construction ongoing; expected operational by end of current financial year; initially dedicated to contract/exclusive manufacturing, especially oilfield services agreement with US company.
→Secondary construction at Site-IV planned for commercialization agreement with Saudi Aramco Technologies on Converge polyols platform.
→Site-V: Regulatory approvals applied, fencing and initial civil work begun; envisioned as a large industrial estate with 16+ production blocks, focusing on sustainability and advanced technology.
→Additional R&D infrastructure expansion underway with a new R&D center expected in 1-2 years.
→Ongoing significant investments in R&D and pilot plants to support CRAMS business and new project pipelines.

How does Aether Industries Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Aether Industries Ltd

Rev 3Mar 1

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Aether Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio